Company
Mobius Therapeutics
Mobius Therapeutics vision is to lead in ophthalmic perioperative pharmaceuticals.
Also known as Mobius Therapeutics, LLC
- Status
- Acquiredas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
- Customers
- ophthalmic surgical suite
- Legal name
- Mobius Therapeutics, LLC
Claim, correct or request removal
Record updated 28 September 2026
About
Our mission is to identify challenging needs and innovate solutions to improve patient care, patient access, and provider safety.
Funding snapshot
- Total raised
- $7.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $5M2013-10-10
Funding rounds
- Round, 2013
- $5M2013-10-10, SEC form D sold, 19 investors
- Round, 2012
- $1.7M2012-10-31, SEC form D sold, 5 investors
- Round, 2010
- $667K2010-09-21, SEC form D sold, 11 investors
About the company
- Status notes
- In May 2025, Mobius Therapeutics became a wholly owned subsidiary of Glaukos Corporation
Products
- Other
- MITOSOL (mitomycin for solution) 0.2 mg/vial Kit
Exit
- Acquisition
- 2025-05
Loading relationship preview